Table 1: Nano-formulations commercial- and currently available.

Product	Company	Drug	Formulation/ROA	Application	Status
Abraxane	Abrasix Bioscience, AstraZeneca	Paclitaxcel	Albumin-bound nanoparticles-iv	Metastatic breast cancer	Marketed
Caelyx	Schering-Plough	Doxorubicin	Pegylated liposome-im	Metastatic breast and ovarian cancer; Kaposi sarcoma	Marketed
Myocet	ZeneusPharma Ltd	Doxorubicin	Liposoma/iv	Metastatic breast cancer	Marketed
Doxil	Sequus Pharmaceutical	Doxorubicin	Liposome/iv	Kaposi sarcoma	Marketed
L-Annamycin	Callisto Pharmaceuticals	Annamycin	Liposome/iv	Children and young adults with refractory or relapsed ALL or AML	Phase I/II
Genexol-PM	Samyang Pharmaceuticals	Paclitaxel	Methoxy PEG-PLA/iv	Breast and lung cancer	Phase II
CALAA-01	Calando Pharmaceuticals	Anti-R2 SiRNA	Cyclodestrin-containing polymer (CAL 101) and targeting agent (AD-PEG-Tf)/iv	Solid tumors that are refractory to standard-of-care	Phase I
Rexin-G	Epeius Biotechnologies	Dominant negative cyclin G1 construct	Pathotropic nanoparticles/iv	Recurrent or metastatic breast cancer	Phase I/II
BikDD Nanoparticle	MD Anderson Cancer Center/NCI	Pro-apoptotic Bik gene (BikDD)	Liposome/iv	Pancreatic Cancer	Phase I
Docetaxel-PNP	Samyang	Docetaxel	Polymeric nanoparticles/iv	Advanced solid malignancies	Phase I

ROA: Route of administration, iv: intravenous, im: intramuscular, ALL: Acutelymphocyticleukemia, AML: Acutemyelogenousleukemia, PEG-PLA: Poly[ethylene glycol]-poly[lactide], Tf: Human transferringprotein, HCC: Hepatocelular carcinoma